Aytu BioPharma Files 8-K: Director Changes, Officer Updates
Ticker: AYTU · Form: 8-K · Filed: May 21, 2025 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 8-K |
| Filed Date | May 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filing
Related Tickers: AYTU
TL;DR
AYTU board shakeup and exec changes filed today.
AI Summary
On May 21, 2025, Aytu BioPharma, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, changes in its officer composition, and updates to compensatory arrangements for its officers. Additionally, the filing covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
Changes in board composition and officer roles can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with votes by security holders, can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- AYTU BIOPHARMA, INC (company) — Registrant
- 0001385818 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 470883144 (company) — EIN
- DE (company) — State of Incorporation
- 0630 (company) — Fiscal Year End
- 001-38247 (company) — SEC File Number
- 25973416 (company) — Film Number
- 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (company) — Business and Mail Address
- AYTU BIOSCIENCE, INC (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but does not specify the names of the individuals elected or any departures.
Were there any changes in the company's executive officers?
Yes, the filing mentions the appointment of certain officers, but does not provide specific names or roles.
What is the nature of the compensatory arrangements updated?
The filing states that compensatory arrangements of certain officers were updated, but the details of these arrangements are not provided in this summary.
What matters were submitted to a vote of security holders?
The filing confirms that matters were submitted to a vote of security holders, but the specific proposals are not detailed here.
What financial statements and exhibits are included with this filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in this summary.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 21, 2025 regarding AYTU BIOPHARMA, INC (AYTU).